S. 4348 would reauthorize the collection and spending of user fees by the Food and Drug Administration for activities related to the approval and marketing of prescription drugs and medical devices. The bill also would amend the Federal Food, Drug, and Cosmetic Act in part to change processes and procedures for regulating, manufacturing, and marketing certain prescription drugs, medical devices, and other products.
